Liver Diseases Therapeutics Market, Therapy Type (Anti-Rejection Drugs/Immunosuppressant’s, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Immunoglobulin’s, Corticosteroids)

Liver Diseases Therapeutics Market, Therapy Type (Anti-Rejection Drugs/Immunosuppressant’s, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Immunoglobulin’s, Corticosteroids), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)- Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

Liver is the largest organ of the human body. It helps to digest food, store energy, and remove poisons. There are many kinds of liver diseases like diseases caused by viruses such as hepatitis A, hepatitis B, and hepatitis C. Diseases can also be caused by drugs, poisons, or too much alcohol consumption. Examples include fatty liver disease and cirrhosis. Live cancer is another growing disease. There are several inherited disorders like hemochromatosis and Wilson disease that affect the liver. The common symptoms of diseases affecting the liver include swelling of the abdomen and legs, bruising easily, Jaundice, and change in color of stool and urine. Imaging tests and liver function tests can check liver damage and diagnose liver disease. Treatments given for liver diseases include anti-rejection drugs/immunosuppressants, chemotherapy drugs, targeted therapy, vaccines, anti-viral drugs, immunoglobulins, and corticosteroids.

Market Dynamics

Increasing prevalence of liver diseases, research and development of novel therapeutics, and approvals from regulatory bodies for liver disease treatment are attributed to the growth of the global liver diseases therapeutics market. For instance, on May 26, 2022, Pfizer Inc., U.S. based pharmaceutical company announced U.S. Food and Drug Administration granted fast-track designation to Pfizer’s investigational combination therapy for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis. Fast Track is a process designed to facilitate the development and expedite the review of new drugs and vaccines intended to treat or prevent serious conditions and address unmet medical needs. The two drugs in combinational therapies are ervogastat and clesacostat. The decision was made based on Pfizer’s nonclinical studies and phase 2a clinical study of drugs which showed reduced liver fat with favorable safety and tolerability profile.

Key features of the study:

• This report provides an in-depth analysis of the global liver diseases therapeutics market and provides market size (US$ Billion) and compound annual growth rate (CAGR) for the forecast period (2023–2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global liver diseases therapeutics market based on the following parameters–Company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Astellas Pharma Inc., Bristol-Myers Squibb, Gilead Sciences, Glaxosmithkline Plc, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A, Pfizer Inc., Takeda Pharmaceutical, Valeant Pharmaceuticals, Watson Pharmaceuticals, Inc., Theratechnologies Inc., Alnylam Pharmaceuticals, Inc., Protagonist Therapeutics, Inc., Dicerna Pharmaceuticals, Inc., Endo International, Provectus Biopharmaceuticals Inc., and MAX BioPharma, Inc..
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global liver diseases therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global liver diseases therapeutics market.

Detailed Segmentation:

• Global Liver Diseases Therapeutics Market, Therapy Type:
• Anti-Rejection Drugs/Immunosuppressant
• Chemotherapy Drugs
• Targeted therapy
• Vaccines
• Anti-Viral Drugs
• Immunoglobulin’s
• Corticosteroids
• Global Liver Diseases Therapeutics Market, By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Global Liver Diseases Therapeutics Market, By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa
• Company Profiles
• Astellas Pharma Inc.
• Bristol-Myers Squibb
• Gilead Sciences
• Glaxosmithkline Plc
• F. Hoffmann-La Roche Ltd.
• Merck & Co. Inc.
• Novartis AG
• Sanofi S.A
• Pfizer Inc.
• Takeda Pharmaceutical
• Valeant Pharmaceuticals
• Watson Pharmaceuticals, Inc.
• Theratechnologies Inc.
• Alnylam Pharmaceuticals, Inc.
• Protagonist Therapeutics, Inc.
• Dicerna Pharmaceuticals, Inc.
• Endo International
• Provectus Biopharmaceuticals Inc.
• MAX BioPharma, Inc.